Early research (Phase 1)Study completedNCT00928330
What this trial is testing
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 57